レボフロキサシン1日間投与による泌尿器科外来検査及び処置後の感染予防効果の検討

Abstract

泌尿器科外来での検査・処置当日に感染予防目的でレボフロキサシン100mgを1日3回内服した219名と, 同様の目的で筋肉注射により抗生物質(硫酸ネチルマイシン100mg又は硫酸ジベカシン100mg)を単回投与された304名の効果を比較した.その結果, レボフロキサシン1日間投与は注射剤と同等の有効性を示し, かつ注射剤よりも安全性が高かった

The clinical efficacy of a single-day oral administration of levofloxacin (LVFX) for the prevention of urinary tract infections (UTI) after urogenital examinations and treatments for outpatients was assessed. A single-day oral administration of LVFX, 100 mg three times a day, was compared to a single dose intra-muscular injection of 100 mg netilmicin sulfate or 100 mg dibekacin sulfate. Three of 219 cases (1.4%) and 7 of 304 cases (2.3%) contracted UTI in the single-day oral administration group and the single dose intra-muscular injection group, respectively. Adverse reactions were observed in 3 of 219 cases (1.4%) and 27 of 304 cases (8.8%) in the single-day oral administration group and the single dose intra-muscular injection group, respectively. In the single dose intra-muscular injection group, UTI and adverse reactions were more severe than in the single-day oral administration group. Therefore, a single-day oral administration of LVFX was superior to a single dose intra-muscular injection of netilmicin sulfate or dibekacin sulfate in the prevention of UTI with less probability of the adverse effects. A single-day oral administration of LVFX was concluded to be sufficient for the prevention of UTI caused by examinations and treatments for outpatients.